Thomas Clark, MD
Family Medicine · Providence, UTNPI 1295741114
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $267,812 of the $332,175 with a category attached, or 80.6%. Lilly USA, LLC accounts for 76.6% of it on its own, with 33 other manufacturers making up the rest. Among family medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 813 payments — averaging $408.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$255K
- Boehringer Ingelheim$45K
- Abbott$17K
- Novo Nordisk$7K
- Corcept Therapeutics$4K
- Eli Lilly$3K
- plus $2K from 28 others
Across 18 payments — averaging $942.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$17K
What the payments were for
- Consulting fees$25,7608%
- Speaking & faculty fees$267,81281%
- Travel & lodging$28,3499%
- Food & beverage$10,1233%
- Education$1310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 575 | $254,560 |
| Boehringer Ingelheim | 96 | $44,622 |
| Abbott | 35 | $16,873 |
| Novo Nordisk | 25 | $7,084 |
| Corcept Therapeutics | 22 | $4,424 |
| Eli Lilly | 5 | $2,860 |
| Insulet Corporation | 3 | $297 |
| Sanofi-aventis U.S. LLC | 4 | $195 |
| Renalytix AI, Inc. | 1 | $188 |
| Medtronic | 10 | $161 |
| Dexcom, Inc. | 5 | $108 |
| Esperion Therapeutics, Inc. | 1 | $102 |
| Johnson & Johnson | 1 | $75 |
| Pfizer | 3 | $61 |
| Amarin Pharma, Inc. | 1 | $59 |
| Exact Sciences | 3 | $50 |
| BETA Bionics, Inc. | 3 | $50 |
| Bayer | 3 | $48 |
| Amgen | 1 | $48 |
| Averitas Pharma Inc. | 1 | $37 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Tandem Diabetes Care, Inc. | 2 | $28 |
| AbbVie | 1 | $26 |
| Novartis | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| BD | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Organon | 1 | $14 |
| Acacia Pharma Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$332,175 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 182 | $157,999 |
| MounjaroTirzepatide | 133 | $157,241 |
| FarxigaDapagliflozin Propanediol | 85 | $64,815 |
| XareltoRivaroxaban | 66 | $44,983 |
| EliquisApixaban | 56 | $42,874 |
| OzempicSemaglutide | 26 | $23,763 |
| MyrbetriqMirabegron | 30 | $18,244 |
| TrulicityDulaglutide | 18 | $16,313 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $12,105 |
| TradjentaLinagliptin | 12 | $4,455 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,457 |
| Rosuvastatin Calcium | 291 | $3,380 |
| Celecoxib | 27 | $2,635 |
| Omeprazole | 116 | $2,601 |
| Famotidine | 98 | $2,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $44,622 | $174,559212 claims |
| Lilly USA, LLCMounjaro, Trulicity | $254,560 | $173,554151 claims |
| AstraZenecaFarxiga | $19 | $64,81585 claims |
| Johnson & JohnsonXarelto | $75 | $44,98366 claims |
| PfizerEliquis | $61 | $42,87456 claims |
| Novo NordiskOzempic | $7,084 | $23,76326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 928 family medicine providers in Utah.
Other family medicine in Providence
- Michael CobbleSandy$1.3M
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
- John TemplemanProvo$17K
- Jordan RobertsHolladay$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.